GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Standalone Financial Statements for the year ended March 31, 2022 152 Right of use asset ( ` in lakhs) Buildings Balance as on April 1, 2021 31,26.43 Additions 1,06.74 Less: Depreciation (14,75.69) Balance as on March 31, 2022 17,57.48 Other financial lease liabilities ( ` in lakhs) Buildings Lease liabilities recognised as at April 1, 2021 34,60.26 Additions 1,02.75 Add: Interest accrued during the period 1,73.70 Less: Payments (17,29.06) Lease liabilities recognised as at March 31, 2022 20,07.65 Current lease liabilities 12,45.30 Non current lease liabilities 7,62.35 Borrowing rate - discounting rate used by the Company The lessee’s weighted average incremental borrowing rate applied to the lease liabilities was 4.23% to 7.59% Note 49 : Earnings per share Year ended March 31, 2022 Year ended March 31, 2021 Profit after tax from continuing operations ` in lakhs 376,57.54 286,68.92 Profit after tax from discontinued operations ` in lakhs 1313,95.04 70,87.84 Profit after tax from continuing and discontinued operations ` in lakhs 1690,52.58 357,56.76 Weighted average number of shares Nos. 16,94,06,034 16,94,06,034 Earnings per share before Exceptional items from continuing operations (Basic and Diluted) (Refer Note (a) below) ` 21.48 27.13 Earnings per share after Exceptional items from continuing operations (Basic and Diluted) ` 22.23 16.92 Earnings per share from discontinued operations (Basic and Diluted) ` 77.56 4.18 Earnings per share before Exceptional items from continuing and discontinued operations (Basic and Diluted) (Refer Note (b) below) ` 99.05 31.32 Earnings per share after Exceptional items from continuing and discontinued operations (Basic and Diluted) ` 99.79 21.11 Face value per share ` 10 10 (a) Earning per share before exceptional items from continuing operations is impacted by tax adjustment for earlier years. Excluding the impact of the same Earning per share for March 31, 2022 is ` 32.58. (b) Earning per share is impacted by profit on Sale of Brands and other identified assets and tax adjustment for earlier years. Adjusting for these, the Earning per share from continuing and discontinued operations for March 31, 2022 is ` 35.68.